Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

1.7K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.7K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.7K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.7K
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

247
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
247

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From Wonder to Anger: <i>Rethinking</i> The Showman and the Slave <i>Through Standpoint Theory</i>.

Perspectives in biology and medicine·2024
Same author

Understanding the role of structural racism in sleep disparities: a call to action and methodological considerations.

Sleep·2022
Same author

Sleeping while disabled, disabled while sleeping.

Sleep health·2017
Same author

Antibiotic Prophylaxis in Orbital Fractures.

The open ophthalmology journal·2017
Same author

Acute vision loss after ocriplasmin use.

Retinal cases & brief reports·2015
Same author

Toward earlier detection of choroidal neovascularization secondary to age-related macular degeneration: multicenter evaluation of a preferential hyperacuity perimeter designed as a home device.

Retina (Philadelphia, Pa.)·2010

Related Experiment Video

Updated: Apr 14, 2026

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

4.5K

Transient vision loss after ocriplasmin injection.

Benjamin Reiss1, Lindsay Smithen, Sam Mansour

  • 1Department of Ophthalmology, The George Washington University, Washington, District of Columbia.

Retina (Philadelphia, Pa.)
|April 23, 2015
PubMed
Summary

Ocriplasmin injections for vitreomacular adhesion frequently cause vision loss, often linked to ellipsoid layer damage on optical coherence tomography. Further research is needed to understand this complication.

More Related Videos

An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach
07:13

An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach

Published on: December 7, 2016

14.1K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

1.2K

Related Experiment Videos

Last Updated: Apr 14, 2026

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

4.5K
An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach
07:13

An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach

Published on: December 7, 2016

14.1K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

1.2K

Area of Science:

  • Ophthalmology
  • Retinal Diseases
  • Ocular Therapeutics

Background:

  • Ocriplasmin is used to treat vitreomacular adhesion.
  • Transient vision loss is a poorly understood complication of ocriplasmin injection.

Purpose of the Study:

  • To investigate the incidence and characteristics of vision loss following ocriplasmin injection.
  • To correlate vision loss with ellipsoid zone integrity on optical coherence tomography (OCT).

Main Methods:

  • Retrospective review of patients receiving ocriplasmin for vitreomacular adhesion.
  • Analysis of optical coherence tomography (OCT) scans for ellipsoid zone loss using MIPAV software.
  • Assessment of visual acuity changes over a 4-week period post-injection.

Main Results:

  • 80% of patients experienced vision loss within the first month after ocriplasmin injection.
  • Average visual acuity significantly decreased from baseline, with a nadir at week 2.
  • Ellipsoid zone loss was observed in 50% of patients, correlating with vision decline.

Conclusions:

  • Vision loss is a common complication of ocriplasmin treatment for vitreomacular adhesion.
  • Loss of the ellipsoid layer on OCT is associated with post-ocriplasmin vision loss.
  • Additional studies are required to fully elucidate this adverse event.